BridgeBio Pharma (BBIO) Highlights PROPEL 3 Data, Is The Valuation Upside Still Open?

BridgeBio Pharma (BBIO) returned to focus after fresh PROPEL 3 data on oral infigratinib in achondroplasia, with management highlighting 52 week trends in sleep apnea, ear infections, growth and body proportionality.

BridgeBio Pharma’s latest PROPEL 3 update lands after a choppy stretch in the market, with the share price at US$72.44 and a 30 day share price return down 13.6%, even as the 1 year total shareholder return is up 41.46% and the 3 year total shareholder return is up 148.68%. This suggests long term momentum remains intact while shorter term sentiment has cooled around recent news and expectations.

Spot 16 high quality undiscovered gems that, like BridgeBio Pharma, are using late-stage clinical data and regulatory milestones to reshape expectations around genetic disease treatment.

BridgeBio Pharma is now being pulled between long term enthusiasm for its genetic disease portfolio and a recent pullback that cooled expectations. Has most of the rerating already happened, or is the valuation still leaving clear upside on the table?

Most Popular Narrative: 189.8% Overvalued

BridgeBio Pharma closed at $72.44 while the leading valuation story pegs fair value at $25.00, so the narrative implies a steep premium to that figure.

The "BridgeBio Commercial Bonanza" is priced for perfection, treating the upcoming Acoramidis launch as an automatic cash cow while ignoring a brutal multi-front commercial dogfight.

Here is why the market is mispricing the structural hurdles for BBIO:

Read the complete narrative.

Curious what keeps this BridgeBio Pharma narrative so cautious at $25.00. The whole case leans on aggressive revenue expansion, rising margins and a rich future profit multiple. Want to see which specific operating assumptions and discount rate have to line up for that to hold.

Result: Fair Value of $25.00 (OVERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

Still, BridgeBio Pharma could surprise this cautious script if commercial execution outperforms expectations or if future clinical updates reset sentiment around key programs.

Find out about the key risks to this BridgeBio Pharma narrative.

Another View on BridgeBio Pharma’s Valuation

The user narrative suggests a fair value of $25.00 for BridgeBio Pharma and describes the stock as overextended. Our DCF model provides a very different result. It values BBIO at $287.39 per share, which frames the current $72.44 price as heavily discounted rather than stretched. Readers may wish to compare these perspectives and consider which analysis they find more convincing.

Look into how the SWS DCF model arrives at its fair value.

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out BridgeBio Pharma for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 31 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

Given how split sentiment is around BridgeBio Pharma, it makes sense to move quickly, review the underlying assumptions and pressure test both sides yourself. To weigh up both the upside arguments and the concerns in one place, start with the 3 key rewards and 1 important warning sign.

Looking for more BridgeBio Pharma style ideas?

If you stop with BridgeBio Pharma, you risk missing out on other compelling setups. Use the Simply Wall St screener to widen your opportunity set with discipline.

• Target resilient balance sheets by filtering for companies on the list of solid balance sheet and fundamentals (23 results) that can better withstand funding shocks and downturn risk.
• Hunt for mispriced quality using the 31 high quality undervalued stocks to surface businesses where fundamentals and current market expectations appear out of sync.
• Dial back risk while staying invested by focusing on the 11 resilient stocks with low risk scores and spotting stocks with steadier financial and volatility profiles.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com